The Women in AI Healthcare event series - hosted by Real Chemistry in collaboration with Pharma Brands – brings together ...

Pfizer and Astellas now have two studies supporting the use of Padcev with MSD's Keytruda as a perioperative therapy for ...

Here’s what most pharma professionals don’t want to hear: if you're a scientist or physician who spent your career in pharma, ...

Shares in the company rose more than 35% on the strength of the data, which could put DBV on track to bring the immunotherapy ...

Privately-held drug developer LIB Therapeutics has claimed FDA approval for a new once-monthly PCSK9 inhibitor – Lerochol – ...

Patients are often stabilised for years on somatostatin analogues; however, progression eventually necessitates ...

Regulators in the UK and US are the first to approve GSK's Exdensur, a long-acting, twice-yearly IL-5 inhibitor for severe ...

And with that increasing complexity come rising costs and the risk of delays that can slow the delivery of critical medicines to patients awaiting treatments – and flatten drug sponsors’ return on ...

The ACIP has been accused of cherry-picking data on side effects – attempting to perpetuate a debunked link between the shots ...

GLP-1 receptor agonists have captured global attention for their ability to drive weight loss and improve metabolic health.

Regeneron has been a bit of a latecomer in the market for BCMA-directed therapies for multiple myeloma, but is pushing to catch up with rival therapies from Johnson & Johnson and Pfizer. At ASH, ...

We knew it was coming, and now it’s close. By the end of 2024, the US Food and Drug Administration (FDA) is expected to formally make reviews by a single institutional review board (sIRB) the standard ...